Table 2 Follow-up changes in the clinical and biochemical characterization of the study population

ΔBMI

(Kg/m²)

− 0.6 [− 5.8; 2.8]

− 0.2 − .3; 4.1]

ns

ΔSystolic Blood Pressure

(mmHg)

− 6 [− 14; 5]

− 8 [− 20; 15]

ns

ΔDiastolic Blood Pressure

(mmHg)

− 2 [− 15; 11]

− 3 [− 16; 5]

ns

ΔFasting glucose

(mmol/L)

− 0.1 [− 2.2; 0.9]

− 0.7 [− 3.8; 0.6]

ns

ΔHbA1_c

(mmol/mol)

− 1 [− 8.25; 2.75]

− 2 [− 14; 3]

ns

ΔeGFR

(ml/min/1·73m²)

0.8 [− 3.0; 4.2]

1.5 [− 2.4; 5.0]

ns

ΔTotal cholesterol

(mmol/L)

0 [− 1.1; 1]

− 0.5 [− 1.4; 0.9]

ns

ΔHDL cholesterol

(mmol/L)

0 [− 0.2; 0.3]

0.2 [− 0.1; 0.4]

ns

ΔLDL cholesterol

(mmol/L)

− 0.1 [− 0.5; 0.9]

− 0.8 [− 1.4; 0.8]

ns

ΔTriglycerides

(mmol/L)

− 0.2 [− 0.8; 0.3]

− 0.2 [− 0.6; 0.8]

ns